Logo
x

Search

Subscribe Now

Takeda

Takeda Reports the MHLW’s Approval of Fruzaqla (Fruquintinib) to Treat Unresectable Advanced or Recurrent Colorectal Cancer (CRC)

Takeda Reports the MHLW’s Approval of Fruzaqla (Fruquintinib) to Treat Unresectable Advanced or Recurrent Colorectal Cancer (CRC)

  • September 25, 2024
Takeda Reports the EC’s Approval of Adzynma to Treat Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda Reports the EC’s Approval of Adzynma to Treat Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

  • August 7, 2024
Takeda’s Fruzaqla Gains the EC’s Approval for the treatment of Metastatic Colorectal Cancer

Takeda’s Fruzaqla Gains the EC’s Approval for the treatment of Metastatic Colorectal Cancer

  • June 25, 2024
Takeda Reports Topline Data from P-III (SKYLINE and SKYWAY) Studies of Soticlestat for Dravet Syndrome (DS) and Lennox-Gastaut Syndrome (LGS)

Takeda Reports Topline Data from P-III (SKYLINE and SKYWAY) Studies of Soticlestat for Dravet Syndrome (DS) and Lennox-Gastaut Syn...

  • June 18, 2024
Takeda Enters into an Option Agreement with Ascentage Pharma for Olverembatinib to Treat Chronic Myeloid Leukemia

Takeda Enters into an Option Agreement with Ascentage Pharma for Olverembatinib to Treat Chronic Myeloid Leukemia

  • June 17, 2024
Takeda’s ADAMTS13 Receives the CHMP’s Positive Opinion for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

Takeda’s ADAMTS13 Receives the CHMP’s Positive Opinion for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

  • May 31, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.